Affimed Therapeutics AG (Affimed)

Oncology Corporate Profile

Company Description

Affimed Therapeutics AG is a therapeutic antibody company developing unique antibody therapeutics as novel treatments for life threatening diseases with high unmet medical needs. The company has generated a growing pipeline of drug candidates based on its proprietary TandAb® antibody platform. Affimed’s product candidates are developed for the treatment of CD19-positive (AFM11) and CD30-positive tumors (AFM13).


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
afm-13bi-specific tetravalent antibody Hodgkin's LymphomaII
afm-13 (+ (pembrolizumab)bi-specific tetravalent antibody Hodgkin's LymphomaI
afm-11bi-specific tetravalent antibody Non-Hodgkin's Lymphoma (NHL)I

View additional information on product candidates here »


Recent News Headlines

There are no news items to display